Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Ogris

Showing results (91-100 of 97) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 97 results.
Cancer Chemotherapy Reports. Part 3|March 1, 1973
Immunologic status before and during immunotherapy (immuneprofile)G Alth, H Denck, M Fischer, et al.
Cancer Chemotherapy Reports. Part 3|March 1, 1973
Aspects of the immunologic treatment of lung cancerG Alth, H Denck, M Fischer, et al.
Journal of the American College of Cardiology|March 1, 1996
Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failureR Pacher, B Stanek, M Hülsmann, et al.
Molecular Biology of the Cell|February 13, 2001
Methylation of the protein phosphatase 2A catalytic subunit is essential for association of Balpha regulatory subunit but not SG2NA, striatin, or polyomavirus middle tumor antigenX X Yu, X Du, C S Moreno, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 1994
Polyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigenK S Campbell, E Ogris, B Burke, et al.
Acta Medica Austriaca. Supplement|January 1, 2003
[Significance of minimal residual disease for the estimation of the prognosis and for therapeutic decisions in solid tumors]W Hinterberger, Veronika Buxhofer, E Ogris, et al.
American Journal of Clinical Oncology|August 24, 2000
Elevation of plasma prolactin in patients undergoing autologous blood stem-cell transplantation for breast cancer: is its modulation a step toward posttransplant immunotherapy?M Hinterberger-Fischer, E Ogris, P Kier, et al.
Pageof 10

Showing results (91-100 of 97) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 97 results.
Cancer Chemotherapy Reports. Part 3|March 1, 1973
Immunologic status before and during immunotherapy (immuneprofile)G Alth, H Denck, M Fischer, et al.
Cancer Chemotherapy Reports. Part 3|March 1, 1973
Aspects of the immunologic treatment of lung cancerG Alth, H Denck, M Fischer, et al.
Journal of the American College of Cardiology|March 1, 1996
Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failureR Pacher, B Stanek, M Hülsmann, et al.
Molecular Biology of the Cell|February 13, 2001
Methylation of the protein phosphatase 2A catalytic subunit is essential for association of Balpha regulatory subunit but not SG2NA, striatin, or polyomavirus middle tumor antigenX X Yu, X Du, C S Moreno, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 1994
Polyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigenK S Campbell, E Ogris, B Burke, et al.
Acta Medica Austriaca. Supplement|January 1, 2003
[Significance of minimal residual disease for the estimation of the prognosis and for therapeutic decisions in solid tumors]W Hinterberger, Veronika Buxhofer, E Ogris, et al.
American Journal of Clinical Oncology|August 24, 2000
Elevation of plasma prolactin in patients undergoing autologous blood stem-cell transplantation for breast cancer: is its modulation a step toward posttransplant immunotherapy?M Hinterberger-Fischer, E Ogris, P Kier, et al.
Pageof 10